Back to first-pass browser

First-pass extracted concept

multiplex-engineered T cells

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

advanced engineered cellular products, multifunction T cells

Extracted Explainers

What the tool is doing

Multiplex-engineered or multifunction T cells are described as single T cells engineered at multiple loci and/or endowed with several new functions.

Source 1DOIPubMed

Resources required

The abstract states that these products rely on currently available cellular engineering technologies, including viral and non-viral approaches such as CRISPR-Cas9.

Source 1DOIPubMed

What problem it solves

They are intended to overcome major shortcomings of adoptive T-cell immunotherapy, including exhaustion, poor trafficking, toxicity, and antigen escape.

Source 1DOIPubMed

What it does not solve

The abstract notes that advanced cell engineering still has limitations and unresolved gaps that must be addressed to optimize efficacy.

Source 1DOIPubMed

Alternatives

The abstract contrasts these advanced products with first-generation genetically modified T-cell therapeutics and more established CAR-modified T cells.

Source 1DOIPubMed

Evidence Snippets

genetically engineer single T cells at multiple different loci and/or confer several novel functions to circumvent the shortcomings of adoptive immunotherapy to treat cancer
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1design strategysupports2025Source 1DOIPubMed

Engineering single T cells at multiple loci and/or conferring several novel functions is proposed to circumvent shortcomings of adoptive immunotherapy for cancer.

Quoted textsource-backed
This review focuses on the promise of using currently available cellular engineering technologies to genetically engineer single T cells at multiple different loci and/or confer several novel functions to circumvent the shortcomings of adoptive immunotherapy to treat cancer.
Claim 2engineering rationalesupports2025Source 1DOIPubMed

Further engineering can address several limitations of first-generation adoptive T-cell therapies and expand the potential of cell therapy.

Quoted textsource-backed
Several of such limitations can be addressed by further engineering, expanding significantly the potential of cell therapy.
Claim 3evidence summarysupports2025Source 1DOIPubMed

Emerging clinical data support the use of multiplex-engineered T cells.

Quoted textsource-backed
emerging clinical data supporting the use of multiplex-engineered T cells
Claim 4limitation statementsupports2025Source 1DOIPubMed

Advanced cell engineering has limitations and remaining gaps that must be addressed to optimize adoptive T-cell immunotherapy efficacy.

Quoted textsource-backed
The limitations of advanced cell engineering and the remaining gaps that need to be filled to optimize the efficacy of adoptive T-cell immunotherapies are also discussed.